Sweden · Delayed Price · Currency is SEK FluoGuide Earnings Call Transcripts
Fiscal Year 2026
-
FDA Fast Track approval and U.S. trial site opening mark key milestones, with two major clinical trials ongoing and strong focus on workflow integration. H1 net loss was DKK 24.6 million, with cash reserves at DKK 50 million. Interim results and new partnerships are expected in H2.
-
No revenues as development continues, with increased R&D spending and a net loss of DKK 11.8 million. Fast Track designation and clinical milestones drive progress, with cash runway through Q1 2027 and key trial results expected soon.
Fiscal Year 2025
-
Three positive Phase II trials, new partnerships, and a strengthened management team marked a pivotal year, with a net loss of DKK 39 million and a strong cash position. Regulatory progress with the FDA and upcoming clinical milestones set the stage for further growth.
-
A novel imaging agent enables surgeons to better identify and remove cancer during surgery, with proven efficacy in multiple cancer types and strong FDA feedback. Market entry is prioritized in the U.S. with broad equipment compatibility and strategic partnerships.